Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

Abstract Background Diffuse large B‐cell lymphoma (DLBCL) patients refractory to rituximab‐based immunochemotherapy have a dismal prognosis. However, the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries. To validate the definition a...

Full description

Bibliographic Details
Main Authors: Shuo Wang, Li Wang, Jianda Hu, Wenbin Qian, Xi Zhang, Yu Hu, Qi Zhu, Bobin Chen, Depei Wu, Chung‐Chou H. Chang, Pengpeng Xu, Xiaoyun Zheng, Juying Wei, Yao Liu, Guohui Cui, Yong Tang, Yan Ma, Haiwen Huang, Hongmei Yi, Weili Zhao
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Communications
Subjects:
diffuse large B‐cell lymphoma
multicenter cohort study
refractory
relapse
rituximab
immunochemotherapy
Online Access:https://doi.org/10.1002/cac2.12126

Internet

https://doi.org/10.1002/cac2.12126

Similar Items